INTRODUCTION {#sec1-1}
============

The miscarriage of three or more consecutive pregnancies in the first or early second trimester is termed as recurrent pregnancy loss (RPL)\[[@ref1]\]. Several etiological factors, including endocrinologic problems, uterine structural, chromosomal anomalies, and antiphospholipid antibody syndrome can be the causes of some RPL cases. However, in many cases, the pathogenesis of RPL remains unknown\[[@ref2],[@ref3]\]. For more than two decades, researchers have focused on certain inherited thrombophilic factors that may be the risk of arterial and/or venous thromboses and their possible association with pregnancy complications such as early pregnancy loss\[[@ref4]\]. It is estimated that the thrombophilia is a common cause of RPL and is found in 40-50% of cases\[[@ref5]\].

Three common inherited thrombophilia markers, namely Factor V Leiden (*FVL*), Prothrombin G20210A (*PT* *G20210A*), and Methylene tetrahydrofolate reductase (*MTHFR*) *C677T* are candidate genes for venous thromboembolism (VTE)\[[@ref5]\]. Various hypotheses were proposed to explain the role of the thrombophilic genes polymorphisms such as *MTHFR C677T*, *MTHFR A1298C*, *Prothrombin G20210A*, *FVL G1691A*, and *PAI-1 4G/5G* in RPL\[[@ref6],[@ref7]\]. A large number of studies have investigated the association between the thrombophilia gene polymorphisms and RPL susceptibility in the Iranian population\[[@ref8]-[@ref25]\]. However, the results were inconsistent or inconclusive, presumably due to the small sample size in these published studies. Undoubtedly, meta-analysis can be used to increase power and answer questions not posed by the individual studies. Therefore, we conducted this systematic review and meta-analysis to investigate the association between the most common polymorphisms of thrombophilic genes (including *MTHFR C677T*, *MTHFR A1298C*, *Prothrombin G20210A*, *FVL G1691A*, and *PAI-1 4G/5G*) and RPL risk in the Iranian population.

MATERIALS AND METHODS {#sec1-2}
=====================

Search strategy {#sec2-1}
---------------

To identify eligible studies for this meta-analysis, we searched the PubMed, Web of Science, Google Scholar databases, ISC, and EMBASE. In the search, we considered all eligible articles published up to April 1, 2017 that examined the association between the *MTHFR C677T*, *MTHFR A1298C*, *Prothrombin G20210A*, *FVL G1691A*, and *PAI-1 4G/5G* polymorphisms and RPL risk in the Iranian population. The following key terms were included in our search: "recurrent pregnancy loss", ''recurrent miscarriage'', ''habitual abortion'', "RPL", "thrombophilic gene", "*MTHFR* *C677T*'', "*MTHFR* A1298C'', "*Prothrombin* G20210A'', "*Factor V Leiden G1691A*'', "*PAI-1 4G/5G*'', "polymorphism", "variant", "gene", "genotype", "SNP", and "allele". The extracted publications were limited to Persian and English languages and conducted only on human subjects. We retrieved those publications matching the keywords without no restriction, and then the studies were evaluated by reading the title and abstract. We have also screened the reference lists of the retrieved articles for original papers. If there were multiple reports of the same study or overlapping data, only the study with the largest sample sizes or the most recent one was selected in our meta-analysis, and the others were excluded.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

The included studies to the meta-analysis had to be consistent with the following criteria: (1) published in full-text, (2) be case-control or cohort design, 3) evaluate the association between *MTHFR C677T*, *MTHFR A1298C*, *Prothrombin G20210A*, *FVL G1691A*, and *PAI-1 4G/5G* polymorphisms and the risk of RPL in the Iranian populations, (4) offered the size of the sample and sufficient data (genotype distributions of both cases and controls were available) for estimating OR with 95% CI, and (5) written in English or Persian. The exclusion criteria were as follows: (1) abstracts, case reports, letter to the editor, and reviews, (2) studies with only case group (no control population), (3) studies on other poly-morphisms of thrombophilic genes, (4) studies without detail genotype frequencies in which calculation of OR is impossible, and (5) duplicate publications of data from the same study.

Data extraction {#sec2-3}
---------------

Two investigators independently extracted the data using a pre-designed form. Based on the inclusion and exclusion criteria, we extracted the following data from each study: the first author, year of publication, number of RPL patients and controls, genotype and allele frequency, minor allele frequencies (MAFs) in control subjects, and Hardy-Weinberg equilibrium (HWE) test in control subjects. For conflicting evaluation, these two investigators carried out discussions until a consensus was reached.

Statistical analysis {#sec2-4}
--------------------

All the statistical analyses were performed by comprehensive meta-analysis (CMA) version 2.0 software (Biostat, USA). All *P* values were two-tailed with a significant level at 0.05. The strength of associations was assessed by using ORs and 95% CIs, and the significance of pooled ORs was examined by Z~test~. We performed a meta-analysis of the association between *MTHFR C677T* polymorphism and RPL under the allelic model (T vs. C), the homozygote model (TT vs. CC), the heterozygote model (CT vs. CC), the dominant model (TT + CT vs. CC), and the recessive model (TT vs. CT + CC). The *MTHFR A1298C* polymorphism was evaluated using the allelic model (C vs. A), the heterozygote model (AC vs. AA), the homozygote model (CC vs. AA), the dominant model (CC + AC vs. AA), and the recessive model (CC vs. AC + AA). The *Prothrombin G20210A* and *FVL G1619A* polymorphisms were assessed under the allelic model (A vs. G), heterozygote model (GA vs. GG), the homozygote model (AA vs. GG), the dominant model (AA + AG vs. GG), and the recessive model (AA vs. AG + GG). *PAI-1 4G/5G* polymorphism was assessed under the allelic model (4G vs. 5G), the heterozygote model (4G/5G vs. 5G/5G), the homozygote (4G/4G vs. 5G/5G), the dominant model (4G/4G + 4G/5G vs. 5G/5G), and the recessive model (4G/4G vs. 4G/5G + 5G/5G). Heterogeneity assumption was checked by a chi-square-based Q-test, and I^2^ statistics was calculated to quantify the proportion of the total variation across studies due to heterogeneity\[[@ref26]\]. The heterogeneity was considered significant if either the Q statistics had *p* \< 0.1 or I^2^ \> 50%. An I^2^ value of 0% represents no heterogeneity, and with the values of 25%, 50%, 75%, or more, it represents low, moderate, high, and extreme heterogeneity, respectively. A *P* value greater than 0.10 indicated the lack of heterogeneity among studies; therefore, the fixed-effects model (Mantel-Haenszel method) was used to calculate pooled OR\[[@ref27]\]. Otherwise, the fixed-effects model (Mantel-Haenszel approach) was used. HWEs were calculated with goodness-of-fit tests (i.e., chi-square or Fisher's exact tests). A value of *p* \< 0.01 signified a departure from HWE\[[@ref28]\]. One-way sensitivity analyses were carried out by consecutively omitting one study at a time to assess the power of the meta-analysis findings\[[@ref29]\]. Visual inspection of the asymmetry of funnel plots was carried out to assess potential publication bias. Begg's funnel plot, a scatter plot of effect against a measure of study size, was generated as a visual aid to detect bias or systematic heterogeneity\[[@ref30]\]. Publication bias was assessed by Egger's test; *p* \< 0.05 was considered statistically significant\[[@ref31]\]. Sensitivity analysis was performed to evaluate the stability of the results by removing the studies, but not in HWE.

RESULTS {#sec1-3}
=======

Characteristics of included studies {#sec2-5}
-----------------------------------

Based on the search criteria, 53 individual literatures were found. After screening the titles and abstracts, 35 publications that did not meet the criteria were excluded. These studies were reviews, short reports, case reports, and other polymorphisms of *MTHFR*, *Prothrombin*, *FVL*, and *PAI*-1 genes. As summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, a total of 37 case-control studies in 18 publications\[[@ref8]-[@ref25]\] were selected in the final meta-analysis, including 1,199 RPL cases and 1,079 controls for *MTHFR C677T* (from ten studies), 1,194 RPL cases and 1079 controls for *MTHFR A1298C* (from ten studies), 630 RPL cases and 594 controls for *Prothrombin G20210A* (from five studies), 830 RPL cases and 794 controls for *FVL G1691A* (from seven studies), and 955 RPL cases and 499 controls for *PAI-1 4G/5G* (from five studies). Genotype distributions in the controls of ten case-control studies were not in agreement with HWE.

###### 

Characteristics of studies included in *MTHFR C677T* and *A1298AC* polymorphisms and RPL

  First author                     Year   Case/Control   Cases    Controls   MAFs     HWE                                                                
  -------------------------------- ------ -------------- -------- ---------- -------- ------- ------- -------- -------- -------- ------- ------- ------- ---------
  **MTHFR C677T**                                        **CC**   **TC**     **TT**   **C**   **T**   **CC**   **TC**   **TT**   **C**   **T**           
                                                                                                                                                         
  Bagheri\[[@ref8]\]               2010   61/53          34       22         5        90      32      27       21       5        75      31      0.292   0.756
  Jeddi-Tehrani\[[@ref9]\]         2011   100/100        43       42         15       128     72      66       25       9        157     43      0.215   \<0.001
  Kazerooni\[[@ref10]\]            2012   60/62          50       6          4        106     14      54       6        2        114     10      0.080   0.006
  Poursadegh Zonouzi\[[@ref11]\]   2012   89/50          53       30         6        136     42      27       22       1        76      24      0.240   0.144
  Idali\[[@ref12]\]                2012   106/100        61       36         9        158     54      66       25       9        157     43      0.215   0.009
  Eskandari\[[@ref13]\]            2013   105/98         43       48         14       134     76      61       30       7        152     44      0.224   0.231
  Khaleghparast\[[@ref14]\]        2014   30/10          13       17         0        43      17      5        5        0        15      5       0.250   0.291
  Yousefian\[[@ref15]\]            2014   204/116        96       90         18       282     126     63       43       10       169     63      0.271   0.497
  Farahmand\[[@ref16]\]            2015   330/350        180      114        36       474     186     230      85       35       545     155     0.221   \<0.001
  Najafian\[[@ref17]\]             2016   114/140        30       48         36       108     120     58       56       0        172     56      0.245   \<0.001
                                                                                                                                                         
  **MTHFR 1298C**                                        **AA**   **CA**     **CC**   **A**   **C**   **AA**   **CA**   **CC**   **A**   **C**           
                                                                                                                                                         
  Bagheri\[[@ref8]\]               2010   61/53          24       28         9        76      46      21       24       8        66      40      0.377   0.791
  Jeddi-Tehrani\[[@ref9]\]         2011   100/100        69       27         4        165     35      94       6        0        194     6       0.030   0.757
  Poursadegh Zonouzi\[[@ref11]\]   2012   89/50          35       46         8        116     62      13       34       3        60      40      0.400   0.003
  Idali\[[@ref12]\]                2012   106/100        40       46         20       126     86      94       6        0        194     6       0.030   0.757
  Sheikhha\[[@ref18]\]             2012   60/60          8        45         7        51      49      34       26       0        94      26      0.216   0.032
  Khaleghparast\[[@ref19]\]        2014   30/10          11       13         6        35      25      5        2        3        12      8       0.040   0.065
  Yousefian\[[@ref15]\]            2014   204/116        98       81         25       277     131     68       39       9        175     57      0.245   0.316
  Farahmand\[[@ref16]\]            2015   330/350        134      152        44       420     240     329      20       1        678     22      0.031   0.250
  Arabkhazaeli\[[@ref19]\]         2016   100/100        100      0          0        200     0       100      0        0        200     0       0.00    0.250
  Najafian\[[@ref17]\]             2016   114/140        30       48         36       108     120     58       56       0        172     56      0.245   \<0.001

MAFs, minor allele frequencies; HWE, Hardy-Weinberg equilibrium

###### 

Characteristics of studies included in *Prothrombin* G20210A, *FVL G1691A*, and *PAI-1 4G/5G* polymorphisms and RPL

  First author                      Year   Case/control   Cases      Controls   MAFs       HWE                                                                          
  --------------------------------- ------ -------------- ---------- ---------- ---------- -------- -------- ---------- ---------- ---------- -------- -------- ------- ---------
  **Prothrombin G20210A**                                 **GG**     **AG**     **AA**     **G**    **A**    **GG**     **AG**     **AA**     **G**    **A**            
                                                                                                                                                                        
  Bagheri\[[@ref8]\]                2011   70/60          48         22         0          118      22       57         3          0          117      3        0.025   0.842
  Kazerooni\[[@ref10]\]             2013   60/60          52         8          0          112      8        54         6          0          114      6        0.050   0.683
  Teremmahi Ardestani\[[@ref21]\]   2013   80/80          80         0          0          160      0        80         0          0          160      0        0.00    0.683
  Parand\[[@ref21]\]                2013   90/44          88         2          0          178      2        43         1          0          87       1        0.011   0.939
  Farahmand \[[@ref16]\]            2015   330/350        316        14         0          646      14       340        10         0          690      10       0.014   0.786
                                                                                                                                                                        
  **FVL 1619 G/A**                                        **GG**     **AG**     **AA**     **G**    **A**    **GG**     **AG**     **AA**     **G**    **A**            
                                                                                                                                                                        
  Bagheri\[[@ref8]\]                2011   70/60          70         0          0          140      0        60         0          0          120      0        0.00    0.786
  Kazerooni\[[@ref10]\]             2013   60/60          43         12         5          98       22       54         4          2          112      8        0.066   0.003
  Torabi\[[@ref22]\]                2012   100/100        87         12         1          186      14       96         4          0          196      4        0.002   0.833
  Teremmahi Ardestani\[[@ref20]\]   2013   80/80          78         2          0          158      2        79         1          0          159      1        0.006   0.955
  Parand\[[@ref21]\]                2013   90/44          72         15         3          159      21       38         6          0          82       6        0.068   0.627
  Farahmand\[[@ref16]\]             2015   330/350        302        28         0          632      28       340        10         0          690      10       0.014   0.786
  Arabkhazaeli\[[@ref19]\]          2016   100/100        95         5          0          195      5        91         9          0          191      9        0.045   0.637
                                                                                                                                                                        
  **PAI-1 4G/5G**                                         **5G5G**   **5G4G**   **4G4G**   **5G**   **4G**   **5G5G**   **5G4G**   **4G4G**   **5G**   **4G**           
                                                                                                                                                                        
  Jeddi-Tehrani\[[@ref9]\]          2011   100/100        60         31         9          151      49       72         27         1          171      29       0.145   0.373
  Aarabi\[[@ref23]\]                2010   54/99          21         23         10         65       43       31         66         2          128      70       0.353   \<0.001
  Idali\[[@ref12]\]                 2012   106/100        35         53         18         123      89       72         27         1          171      29       0.145   0.373
  Khosravi\[[@ref24]\]              2013   595/100        128        208        85         464      378      72         27         1          171      29       0.145   0.373
  Shakarami\[[@ref25]\]             2015   100/100        33         50         17         116      84       45         50         5          140      60       0.300   0.056

MAFs, minor allele frequencies; HWE, Hardy-Weinberg equilibrium

Quantitative synthesis {#sec2-6}
----------------------

[Table 3](#T3){ref-type="table"} listed the main results of the meta-analysis of *MTHFR* C677T and *A1298C* polymorphisms and RPL risk in the Iranian population. When all the eligible studies were pooled into the meta-analysis of *MTHFR* C677T polymorphism, a significant increased risk of RPL was observed in the allelic model (T vs. C: OR = 1.700, 95% CI = 1.208-2.393, *p* = 0.002), the heterozygote model (CT vs. CC: OR = 1.670, 95% CI = 1.215-2.295, *p* = 0.002), the homozygote model (TT vs. CC: OR = 2.409, 95% CI = 1.291-4.497, *p* = 0.006), the dominant model (TT + CT vs. CC: OR = 1.847, 95% CI = 1.264-2.699, *p* = 0.002, [Fig. 1A](#F1){ref-type="fig"}), and the recessive model (TT vs. CT + CC: OR = 1.858, 95% CI = 1.087-3.177, *p* = 0.024). In addition, when all the eligible studies were pooled into the meta-analysis of *MTHFR A1298C* polymorphism, a significant association was observed in the allelic model (C vs. A: OR = 3.190, 95% CI = 1.467-6.936, *p* = 0.003), the heterozygote model (AC vs. AA: OR = 0.344, 95% CI = 1.344-8.321, *p* = 0.009), the homozygote model (CC vs. AA: OR = 5.073, 95% CI = 1.710-15.051, *p* = 0.003, [Fig. 1B](#F1){ref-type="fig"}), the dominant model (CC + AC vs. AA: OR = 4.006, 95% CI = 1.578-10.169, *p* = 0.003), and the recessive model (CC vs. AC + AA: OR = 5.061, 95% CI = 1.668-15.361, *p* = 0.004).

###### 

The meta-analysis of thrombophilic genes polymorphisms and RPL risk

  Polymorphism          Study Number   Genetic Model             Type of Model   Heterogeneity   Odds Ratio   Publication Bias                                            
  --------------------- -------------- ------------------------- --------------- --------------- ------------ ------------------ -------------- ------- --------- ------- -------
  MTHFR C677T                                                                                                                                                             
                        11             T vs. C                   Random          83.71           \<0.001      1.700              1.208-2.393    3.044   0.002     0.533   0.854
                        11             TC vs. CC                 Random          64.10           0.002        1.670              1.215-2.295    3.163   0.002     0.275   0.459
                        10             TT vs. CC                 Random          69.40           0.001        2.409              1.291-4.497    2.761   0.006     0.107   0.132
                        11             TT + TC vs. CC            Random          78.55           \<0.001      1.847              1.264-2.699    3.171   0.002     0.640   0.743
                        10             TT vs. TC + CC            Random          60.50           0.007        1.858              1.087-3.177    2.264   0.024     0.020   0.056
  MTHFR A1298C                                                                                                                                                            
                        9              C vs. A                   Random          94.60           \<0.001      3.190              1.467-6.936    2.928   0.003     0.754   0.752
                        9              CA vs. AA                 Random          92.68           \<0.001      3.344              1.344-8.321    2.595   0.009     0.602   0.995
                        9              CC vs. AA                 Random          70.70           \<0.001      5.073              1.710-15.051   2.927   0.003     0.076   0.015
                        9              CC + CA vs. AA            Random          93.67           \<0.001      4.006              1.578-10.169   2.920   0.003     0.916   0.937
                        9              CC vs. CA + AA            Random          74.31           \<0.001      5.061              1.668-15.361   2.863   0.004     0.348   0.022
  Prothrombin G20210A                                                                                                                                                     
                        4              A vs. G                   Fixed           45.61           0.138        1.979              1.128-3.472    2.379   0.017     0.308   0.902
                        4              AA + AG vs. GG            Fixed           52.94           0.095        2.060              1.162-3.652    2.474   0.013     0.308   0.881
  FVL 1619 G/A                                                                                                                                                            
                        6              A vs. G                   Fixed           41.08           0.131        2.252              1.504-3.373    3.942   \<0.001   0.452   0.572
                        5              AG vs. GG                 Fixed           43.13           0.134        1.695              0.980-2.932    1.888   0.059     0.462   0.786
                        3              AA vs. GG                 Fixed           0.00            0.995        3.277              0.861-12.473   1.740   0.082     1.000   0.425
                        6              AA + AG vs. GG            Fixed           44.02           0.112        2.217              1.447-3.395    3.658   \<0.001   0.452   0.626
                        3              AA vs. AG + GG            Fixed           0.00            0.985        2.867              0.756-10.868   1.549   0.121     1.000   0.333
  PAI-1 4G/5G                                                                                                                                                             
                        5              4G vs. 5G                 Random          75.26           0.003        2.159              1.427-3.244    3.244   \<0.001   0.806   0.925
                        5              4G/5G vs. 5G/5G           Random          86.95           \<0.001      1.799              0.852-3.796    1.541   0.123     0.220   0.087
                        5              4G/4G vs. 5G/5G           Fixed           32.94           0.202        9.811              4.782-20.130   6.227   \<0.001   0.462   0.071
                        5              4G/4G + 4G/5G vs. 5G/5G   Random          79.84           0.001        1.961              1.104-3.484    2.298   0.022     0.806   0.427
                        5              4G/4G vs. 4G/5G + 5G/5G   Fixed           22.62           0.270        10.161             4.975-20.754   6.363   \<0.001   0.462   0.050

![Forest plot of RPL susceptibility associated with thrombophilic genes polymorphisms. (A) *MTHFR C677T* (dominant model: TT + CT vs. CC); (B) *MTHFR A1298C* (homozygote model; AA vs. CC); (C) *Prothrombin* *G20210A* (allele model; A vs. G); (D) *FVL G1619A* (heterozygote model: GA vs. GG), and (E) *PAI-1 4G/5G* (dominant model: 4G/4G + 4G/5G vs. 5G/5G). For each study, the estimation of OR and its 95% CI are plotted with a square and a horizontal line. A diamond indicates the pooled OR with 95% CI.](IBJ-22-78-g001){#F1}

[Table 3](#T3){ref-type="table"} summarizes the ORs with corresponding 95% CIs for association of *Prothrombin G20210A*, *FVL G1691A*, and *PAI-1 4G/5G* polymorphisms with RPL risk in the Iranian population. Among the eligible studies were pooled to the meta-analysis of *Prothrombin G20210A* polymorphism, only allelic and dominant model was applicable because they provided the genotypes of AA + GA vs. GG. Therefore, the pooled analyses showed a significant association between *Prothrombin G20210A* polymorphism and RPL in the Iranian population in the allelic model (A vs. G: OR = 1.979, 95% CI = 1.128-3.472, *p* = 0.017, [Fig. 1C](#F1){ref-type="fig"}) and the dominant model (AA + GA vs. GG: OR = 2.060, 95% CI = 1.162-3.652, *p* = 0.013). When all the eligible studies were pooled into the meta-analysis of *FVL G1691A* polymorphism, we observed a significant increased risk of RPL under allelic model (A vs. G: OR = 2.252, 95% CI = 1.504-3.373, *p* \< 0.001, [Fig. 1D](#F1){ref-type="fig"}) and dominant model (AA+GA vs. GG: OR = 2.217, 95% CI = 1.447-3.395, *p* \< 0.001), but not in the heterozygote model (AG vs. GG: OR = 1.695, 95% CI = 0.980-2.932, *p* = 0.059), the homozygote (AA vs. GG: OR = 3.277, 95% CI = 0.861-12.473, *p* = 0.082), and the recessive model (AA vs. AG + GG: OR=2.867, 95% CI = 0.756-10.868, *p* = 0.121). In addition, there was a significant association between *PAI-1 4G/5G* polymorphism and RPL in the

Iranian population in the allelic model (4G vs. 5G: OR = 2.159, 95% CI = 1.427-3.244, *p* \< 0.001), the homozygote model (4G/4G vs. 5G/5G: OR = 9.811, 95% CI = 4.782-20.130, *p* \< 0.001), the dominant model (4G/4G + 4G/5G vs. 5G/5G: OR = 1.961, 95% CI = 1.104-3.484, *p* = 0.022, [Fig. 1E](#F1){ref-type="fig"}), and the recessive model (4G/4G vs. 4G/5G + 5G/5G: OR = 10.161, 95% CI = 4.975-20.754, *p* \< 0.001), but not in the heterozygote model (4G/5G vs. 5G/5G: OR = 1.799, 95% CI = 0.852-3.796, *p* = 0.123).

Sensitivity analysis {#sec2-7}
--------------------

To evaluate the influence of individual studies on the risk of RPL, the studies were sequentially deleted from this meta-analysis, and the pooled ORs were performed. However, the results did not change exactly, which verify that no individual studies significantly affected the pooled ORs. Additionally, sensitivity analysis was performed after excluding HWE-violating studies, and the corresponding pooled ORs were not materially altered, indicating that our results are statistically robust (not shown).

Publication Bias {#sec2-9}
----------------

In this meta-analysis, Begg's funnel plot and Egger's test were used to assess the publication bias of included studies. The funnel plot revealed no obvious publication bias for *MTHFR* A1298C, *Prothrombin* G20210A, *FVL G1691A*, and *PAI-1 4G/5G*, and this result was confirmed by Begg's test and Egger's test ([Fig. 2](#F2){ref-type="fig"}). However, the shapes of the funnel plots revealed obvious asymmetry for *MTHFR* *C677T* and *MTHFR A1298C* in the recessive model ([Fig. 2A](#F2){ref-type="fig"}), suggesting that there were obvious publication biases in these two genetic models. Moreover, the results of Egger's regression test provided sufficient evidence for publication bias for *MTHFR A1298C* in the recessive model (P~Begg's~ = 0.348, P~Egger's~ = 0.022), but not for *MTHFR* *C677T (P*~Begg's~ = 0.020, P~Egger's~ = 0.056*)*. Therefore, we used the Duval and Tweedie non-parametric "trim-and-fill" method to adjust the results of publication bias for *MTHFR A1298C* polymorphism recessive model. However, the meta-analysis with and without ''trim-and-fill'' method did not show different results, showing that the results of this meta-analysis are statistically robust.

![Begg's funnel plots for thrombophilia gene polymorphisms and RPL risk in the Iranian patients to test the publication bias. (A) *MTHFR C677T* (recessive model: TT vs. CT + CC); (B) *MTHFR A1298C* (dominant model: AA vs. AC + CC); (C) *Prothrombin* G20210A (dominant model: AA + GA vs. GG); (D) *FVL G1691A* (allele model: A vs. G). Each point represents a separate study for the indicated association.](IBJ-22-78-g002){#F2}

DISCUSSION {#sec1-4}
==========

It is known that folate is required for the proper development of fetus and placenta\[[@ref32]\]. Aberrations in folate pathway such as maternal folate deficiency, maternal hyperhomocysteinemia, and either *MTHFR C677T* or *A1298C* polymorphisms were found to contribute to the etiology of RPL in different populations\[[@ref33]\]. Although *MTHFR A1298C* poly-morphism may not responsible for increased total homocysteine, it seems that this polymorphism contributes significantly to the increased homocysteine levels\[[@ref34],[@ref35]\]. Previous studies have reported that *MTHFR C677T* polymorphism is significantly associated with the increased risk of RPL. For instance, Chen *et al*.\[[@ref36]\] in a meta-analysis of 16 articles involving 1420 cases with RPL and 1408 controls reported that *MTHFR C677T* was significantly associated with RPL risk in the Chinese population under all genetics models. Similarly, Wu *et al*.\[[@ref37]\] and Cao *et al*.\[[@ref38]\] findings supported that the idea that *MTHFR C677T* polymorphism was associated with the increased risk of RPL among Asians, but not Caucasians. Based on these studies, the *MTHFR 677TT* polymorphism has a significant increased likelihood of RPL in Asians, which is in agreement with our conclusion. The data of a meta-analysis by Nair *et al*.\[[@ref39]\] showed that *MTHFR A1298C* polymorphism was a genetic risk factor for RPL. However, Cao *et al*.\[[@ref38]\] did not find any significant association between *MTHFR A1298C* polymorphism and RPL susceptibility. The combined data, based on previous studies, showed that both *MTHFR C677T* and *MTHFR A1298C* polymorphisms might be a risk factor for RPL.

As for the other two polymorphisms, we also find a significant association of polymorphisms in *Prothrombin G20210A*, *FVL G1691A*, and *PAI-1 4G/5G* with the risk of RPL, which were consistent with the majority but not all previous studies\[[@ref40]-[@ref42]\]. In a meta-analysis conducted by Gao *et al*.\[[@ref41]\], the *Prothrombin G20210A* variant was reported to increase the risk of RPL (fetal loss, primary RPL, or secondary RPL)\[[@ref43]\], particularly in Europeans and women older than 29 years. In another meta-analysis, Kovalevsky *et al*.\[[@ref44]\] found that *FVL G1691A* or *Prothrombin* gene polymorphisms were associated with the increased risk of two or more miscarriages compared with women without these polymorphisms. In addition, in three meta-analyses, Chen *et al*.\[[@ref45]\], Su *et al*.\[[@ref46]\] and Li *et al*.\[[@ref47]\] suggested that *PAI-1 4G/5G* polymorphism might be associated with RPL development.

Between-study heterogeneity, a multifactorial phoneme in meta-analyses, is a potential problem when interpreting the results\[[@ref48]-[@ref50]\]. In addition to ethnicity and the source of controls, selection of controls, race variation, age, gender, and prevalence of lifestyle factors might also generate the heterogeneity\[[@ref35],[@ref48],[@ref49]\]. In the present meta-analysis, between-study heterogeneity was observed in all polymorphisms, and thus a random-effect model was used for those genetic models.

There was an inevitable publication bias in our meta-analysis because we retrieved only published studies. Publication bias was assessed by funnel plots whose symmetries were further evaluated by Egger's linear regression tests. We have suggested that for the recessive model, the publication bias might be owing to the limited number of the selected studies. Therefore, the negative results in our meta-analysis are possibly due to the limited number of publications to determine statistical significance.

To the best of our knowledge, there is no earlier study on the analysis of thrombophilia gene polymorphisms in RPL in the Iranian population. However, in interpreting results of this meta-analysis, some limitations should be addressed. First, there was no sufficient number of relevant studies to explore more comprehensive association between the thrombophilic genes and RPL in the Iranian patients. Second, in this meta-analysis, only published studies were searched. It is possible that some important unpublished studies that meet our inclusion criteria were missed and ignored in the literature search. Therefore, inevitable publication bias might be exist, which could eventually help explain the possible existence of publication bias in the recessive model. Third, the Iranian population is mixed of different ethnicities, including Persian, Azeri, Kurdish, Lurs, Gilaki, Balochi, etc. However, we did not conduct subgroup analyses because insufficient data were available from the primary literature search. Moreover, due to limited individual data, a more precise analysis on other covariates, such as age, number of abortions, and environmental factors should be performed. As a result, more studies with large sample sizes in view of these factors are also desired. Finally, due to the lack of the original data, we did not take potential interactions among gene-gene (especially thrombo-philic genes interactions), gene-environment, or even different polymorphism loci of the same gene, which all may affect RPL risk in the population.

In conclusion, based on the available evidence, the current meta-analysis demonstrates that there is a significant association between the *MTHFR C677T*, *MTHFR A1298C*, *Prothrombin G20210A*, *FVL G1691A*, and *PAI-1 4G/5G* polymorphisms and RPL risk in the Iranian population. In addition, the direction of further research with a larger sample size should focus not only on the simple relationship of thrombophilic genes polymorphisms and RPL risk but also on gene-gene and gene-environment interactions.
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